Search

Your search keyword '"Kahn S"' showing total 447 results

Search Constraints

Start Over You searched for: "Kahn S" Remove constraint "Kahn S" Topic type 2 diabetes Remove constraint Topic: type 2 diabetes
447 results on '"Kahn S"'

Search Results

2. FTO predicts weight regain in the Look AHEAD clinical trial.

3. Interactions between genetic background, insulin resistance and β-cell function.

4. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe.

5. Truncated (des-[27–31]) C-peptide is not a major secretory product of human islets Paoletta et al.: Truncated C-peptide in human islets.

6. beta-cell dysfunction and failure in type 2 diabetes: potential mechanisms.

7. beta-cell glucokinase deficiency and hyperglycemia are associated with reduced islet amyloid deposition in a mouse model of type 2 diabetes.

8. Oophorectomy promotes islet amyloid formation in a transgenic mouse model of Type II diabetes.

9. Efficacy and Safety of SGLT2 Inhibitors in Pediatric Patients and Young Adults: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials.

10. Empagliflozin Use Is Associated With Lower Risk of All‐Cause Mortality, Hospitalization for Heart Failure, and End‐Stage Renal Disease Compared to DPP‐4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study

11. Tirzepatide's innovative applications in the management of type 2 diabetes and its future prospects in cardiovascular health.

12. Two novel immortal pancreatic beta-cell lines expressing and secreting human islet amyloid polypeptide do not spontaneously develop islet amyloid.

13. Autonomic modulation by SGLT2i or DPP4i in patients with diabetes favors cardiovascular outcomes as revealed by skin sympathetic nerve activity.

14. Advancements in glucagon-like peptide-1 receptor agonist therapy for type 2 diabetes.

15. Insulin Resistance, a Risk Factor for Alzheimer's Disease: Pathological Mechanisms and a New Proposal for a Preventive Therapeutic Approach.

16. The Role of Fecal Microbiota Transplantation (FMT) in the Management of Metabolic Diseases in Humans: A Narrative Review.

17. Growth differentiation factor 15 is not modified after weight loss induced by liraglutide in South Asians and Europids with type 2 diabetes mellitus.

18. Association of dipeptidyl peptidase-4 inhibitor and recurrent pancreatitis risk among patients with type 2 diabetes: A retrospective cohort study.

19. Insufficient Plasma Melatonin and Its Association With Neuropsychiatric Impairments in Patients With T2DM.

20. High-Intensity Interval Versus Moderate-Intensity Continuous Exercise Training on Glycemic Control, Beta Cell Function, and Aerobic Fitness in Women with Type 2 Diabetes.

21. Evaluation of the auditory brainstem response test in patients with type 2 diabetes mellitus.

22. Therapy of Type 2 Diabetes.

23. Intermuscular adipose tissue accumulation is associated with higher tissue sodium in healthy individuals.

24. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, anti-diabetic drugs in heart failure and cognitive impairment: potential mechanisms of the protective effects.

25. Improving glycemic control: transitioning from dulaglutide to tirzepatide in patients with type 2 diabetes undergoing hemodialysis.

26. Identification of common genes and pathways between type 2 diabetes and COVID-19.

27. Ziabetus (Prediabetes): A Harbinger of Critical Stage in the Continuum of Glucose Metabolism Disorder: A Review.

28. The role of thrombolytic protein therapy in the prevention of microvascular complications in non-insulin-dependent diabetes mellitus: an integrative approach.

29. Evaluating the effectiveness of a novel somatostatin receptor 2 antagonist, ZT-01, for hypoglycemia prevention in a rodent model of type 2 diabetes.

30. Lab-on-chip technologies for exploring the gut–immune axis in metabolic disease.

31. Distinguishing islet amyloid polypeptide fibril structures with infrared isotope-label spectroscopy.

32. Exosomes as Emerging Regulators of Immune Responses in Type 2 Diabetes Mellitus.

33. Fecal Microbiota Transplantation: A Prospective Treatment for Type 2 Diabetes Mellitus.

34. Racial/ethnic and socioeconomic disparities in achievement of treatment goals within a clinical trial: a secondary analysis of the ACCORD trial.

35. Incidence Trends of Type 2 Diabetes Mellitus, Medication-Induced Diabetes, and Monogenic Diabetes in Canadian Children, Then (2006–2008) and Now (2017–2019).

36. Lonicera caerulea L. polyphenols improve short-chain fatty acid levels by reshaping the microbial structure of fermented feces in vitro.

37. Increased Insulin Secretion and Glucose Effectiveness in Obese Patients with Type 2 Diabetes following Bariatric Surgery.

38. Examining the associations between testosterone and biomarkers as men age.

39. Association of poor sleep and HbA1c in metformin‐treated patients with type 2 diabetes: Findings from the UK Biobank cohort study.

40. A Mediterranean-Style Diet Improves the Parameters for the Management and Prevention of Type 2 Diabetes Mellitus.

41. PEGylated exenatide injection (PB-119) improves beta-cell function and insulin resistance in treatment-naïve type 2 diabetes mellitus patients.

42. Exosomes as biomarkers and therapy in type 2 diabetes mellitus and associated complications.

43. Experiences and perceptions of self‐management in people with prediabetes: A qualitative meta‐synthesis.

44. Targeting metabolic pathways: a novel therapeutic direction for type 2 diabetes.

45. Differentially Expressed Genes Regulating Glutathione Metabolism, Protein-Folding, and Unfolded Protein Response in Pancreatic β-Cells in Type 2 Diabetes Mellitus.

46. β-Cell function during a high-fat meal in young versus old adults: role of exercise.

47. A flavonoid-rich fraction of Euphorbia peplus attenuates hyperglycemia, insulin resistance, and oxidative stress in a type 2 diabetes rat model.

48. Geroprotective interventions in the 3xTg mouse model of Alzheimer's disease.

49. Initial Insights into the Genetic Variation Associated with Metformin Treatment Failure in Youth with Type 2 Diabetes.

50. Renoprotective Effect of Thai Patients with Type 2 Diabetes Mellitus Treated with SGLT-2 Inhibitors versus DPP-4 Inhibitors: A Real-World Observational Study.

Catalog

Books, media, physical & digital resources